Article Text
Abstract
Moral evaluation of risk/benefit in early phase studies requires assessing the clinical promise of a candidate intervention using preclinical evidence. Yet, there is little to guide ethics committees, investigators, sponsors or other stakeholders morally charged with making these assessments (‘evaluators’). In what follows, we draw on published guidelines for preclinical study design to develop a structured process for assessing the clinical promise of new interventions. In the first step, evaluators gather all relevant preclinical studies, assess the magnitude of treatment effects and determine clinical promise in light of various threats to valid clinical inference. In the second step, evaluators adjust the assessments of clinical promise from preclinical studies by examining how other agents in the same reference class—and supported by similar evidence—have fared in clinical development. Assessments of clinical promise can then be fed into the moral evaluation of risk and benefit in early phase trials. Though our approach has limitations, it offers a systematic and transparent method for assessing risk/benefit in early phase trials of novel interventions.
- Animal Experimentation
- Clinical trials
- Research Ethics
- Scientific Research
- Stem Cell Research
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them
- First - in - human HIV - remission studies: reducing and justifying risk
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T - VEC): a systematic review
- Contractualist reasoning, HIV cure clinical trials, and the moral (ir) relevance of the risk / benefit ratio
- ‘ Rethinking “ Disease ”: a fresh diagnosis and a new philosophical treatment ’
- T-cell agonists in cancer immunotherapy
- Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
- T lymphocyte - targeted immune checkpoint modulation in glioma
- Oxford vaccine study highlights pick and mix approach to preclinical research
- Intraocular pressure efficacy of glaucoma medications versus placebo in phase II compared to later phase trials